NCT06506461View on ClinicalTrials.gov

Gene Editing For Sickle Cell Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2032

Conditions
Sickle Cell Disease
Interventions
DRUG

Plerixafor

Given Subcutaneous (under the skin)

DRUG

Busulfan

Given Intravenous (IV)

BIOLOGICAL

Gene-modified CD34+ cells

Given Intravenous (IV)

DRUG

Motixafortide

Given Subcutaneous (under the skin)

Trial Locations (1)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER